Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
- Author(s)
- Sharma, S; Chung, CY; Uryu, S; Petrovic, J; Cao, J; Rickard, A; Nady, N; Greasley, S; Johnson, E; Brodsky, O; Khan, S; Wang, H; Wang, Z; Zhang, Y; Tsaparikos, K; Chen, L; Mazurek, A; Lapek, J; Kung, PP; Sutton, S; Richardson, PF; Greenwald, EC; Yamazaki, S; Jones, R; Maegley, KA; Bingham, P; Lam, H; Stupple, AE; Kamal, A; Chueh, A; Cuzzupe, A; Morrow, BJ; Ren, B; Carrasco-Pozo, C; Tan, CW; Bhuva, DD; Allan, E; Surgenor, E; Vaillant, F; Pehlivanoglu, H; Falk, H; Whittle, JR; Newman, J; Cursons, J; Doherty, JP; White, KL; MacPherson, L; Devlin, M; Dennis, ML; Hattarki, MK; de Silva, M; Camerino, MA; Butler, MS; Dolezal, O; Pilling, P; Foitzik, R; Stupple, PA; Lagiakos, HR; Walker, SR; Hediyeh-Zadeh, S; Nuttall, S; Spall, SK; Charman, SA; Connor, T; Peat, TS; Avery, VM; Bozikis, YE; Yang, Y; Zhang, M; Monahan, BJ; Voss, AK; Thomas, T; Street, IP; Dawson, SJ; Dawson, MA; Lindeman, GJ; Davis, MJ; Visvader, JE; Paul, TA;
- Journal Title
- Cell Chemical Biology
- Publication Type
- epub ahead of print
- Abstract
- KAT6A, and its paralog KAT6B, are histone lysine acetyltransferases (HAT) that acetylate histone H3K23 and exert an oncogenic role in several tumor types including breast cancer where KAT6A is frequently amplified/overexpressed. However, pharmacologic targeting of KAT6A to achieve therapeutic benefit has been a challenge. Here we describe identification of a highly potent, selective, and orally bioavailable KAT6A/KAT6B inhibitor CTx-648 (PF-9363), derived from a benzisoxazole series, which demonstrates anti-tumor activity in correlation with H3K23Ac inhibition in KAT6A over-expressing breast cancer. Transcriptional and epigenetic profiling studies show reduced RNA Pol II binding and downregulation of genes involved in estrogen signaling, cell cycle, Myc and stem cell pathways associated with CTx-648 anti-tumor activity in ER-positive (ER+) breast cancer. CTx-648 treatment leads to potent tumor growth inhibition in ER+ breast cancer in vivo models, including models refractory to endocrine therapy, highlighting the potential for targeting KAT6A in ER+ breast cancer.
- Publisher
- Cell Press
- Keywords
- CTx-648; Kat6a; Kat6b; Pf-9363; breast cancer; cell cycle; epigenetics; estrogen receptor; resistance
- Research Division(s)
- Bioinformatics; Cancer Biology And Stem Cells; Epigenetics And Development; Personalised Oncology
- PubMed ID
- 37557181
- Publisher's Version
- https://doi.org/10.1016/j.chembiol.2023.07.005
- Open Access at Publisher's Site
https://doi.org/10.1016/j.chembiol.2023.07.005- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-16 02:59:36
Last Modified: 2023-08-16 03:15:34